Background and Aim. A year after the official declaration of the end of the pandemic, this study aimed to assess the epidemic situation by testing a small group of individuals for the presence of the SARS-CoV-2 virus and neutralizing antibodies. Materials and Methods. Nasopharyngeal swabs were collected to isolate SARS-CoV-2 virus in cell culture, while venous blood samples were tested for neutralizing antibodies using a quantitative neutralization reaction. The study included 20 participants (approximately 10% of the team), of whom 16 had been vaccinated against COVID-19, and 4 remained unvaccinated. Vaccinated individuals included 4 who received Sputnik V (over 30 months prior) and 12 who received QazCOVID-in. Results. All 20 participants demonstrated neutralizing antibodies against the Wuhan variant of the virus. For the Delta and Omicron variants, 19 participants showed neutralizing antibodies. Average antibody titers were 6.4 ± 1.39 log₂ for the Wuhan variant, 6.2 ± 1.89 log₂ for the Delta variant, and 4.75 ± 1.84 log₂ for the Omicron variant. Conclusion. The study highlights the persistence of antibodies against SARS-CoV-2 among both vaccinated and unvaccinated participants, though variation in neutralization efficacy was observed among different virus variants. These findings emphasize the importance of monitoring immune responses to track population-level immunity and guide future vaccination strategies.
27 June 2025 in HERALD OF SCIENCE OF S SEIFULLIN KAZAKH AGRO TECHNICAL RESEARCH UNIVERSITY: Veterinary sciences
Crimean-Congo Hemorrhagic Fever (CCHF) is a high mortality, tick-borne viral illness endemic to Africa, Asia, the Middle East, and certain regions of Europe. Notwithstanding its peril to public health, there is presently no licensed vaccination available. This study highlights important progress and challenges in developing CCHF vaccines, including traditional methods (inactivated and live-attenuated vaccines) and new approaches (subunit, DNA, mRNA, and viral vectors). We also investigate the functions of adjuvants and delivery technologies – such as nanoparticles and viral vectors – in enhancing immunogenicity and safety. Insights from historical endeavors and recent advancements underscore the pressing necessity for safe, effective, and scalable vaccinations, especially in endemic areas. Future initiatives must emphasize cross-protective formulations, thermal stability, and international cooperation.